Review anchor
Polyunsaturated fatty acid 5-lipoxygenase
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
Evidence Snapshot
Polyunsaturated fatty acid 5-lipoxygenase
CHEMBL5211
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Polyunsaturated fatty acid 5-lipoxygenase as ChEMBL target CHEMBL5211, mapped to UniProt P48999. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5211
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P48999
Polyunsaturated fatty acid 5-lipoxygenase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Polyunsaturated fatty acid 5-lipoxygenase matters
Polyunsaturated fatty acid 5-lipoxygenase is reviewed as Polyunsaturated fatty acid 5-lipoxygenase (UniProt P48999); the current evidence base includes 1 approved drug, 106 compounds, and 14 assays, with lead potency reaching pChEMBL 9.2.
Protein context
Polyunsaturated fatty acid 5-lipoxygenase
Polyunsaturated fatty acid 5-lipoxygenase Sequence length is 674 aa.
Review this target as Polyunsaturated fatty acid 5-lipoxygenase, mapped to UniProt P48999. Sequence length is 674 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P48999
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 106 compounds, and 14 assays for this target. The dominant activity type is IC50. CHEMBL22106 is the current potency anchor at pChEMBL 9.2.
Use CHEMBL22106 as the tractability anchor when discussing potency (pChEMBL 9.2).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Polyunsaturated fatty acid 5-lipoxygenase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P48999, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
106
Total Compounds
14
Total Assays
1
Approved Drugs
IC50: 68.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL22106
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL21880
|
8.9 | IC50 | — |
|
|
No preferred name
CHEMBL442334
|
8.8 | IC50 | — |
|
|
No preferred name
CHEMBL20599
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL70191
|
8.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZILEUTON
CHEMBL93
|
1996 |
Source Header